Drug Profile


Alternative Names: HANP; hANP(99-126); Human atrial natriuretic peptide; SUN 4936; SUN 4936h; SUN 4936r; SUN Y4936r

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Asubio Pharma
  • Developer Asubio Pharma; Asubio Pharmaceuticals; Zeria
  • Class Amino acids; Heart failure therapies; Natriuretic peptides; Peptides
  • Mechanism of Action Atrial peptide agonists; Diuretics; Natriuretic peptide stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute heart failure
  • Discontinued Adult respiratory distress syndrome; Myocardial infarction

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 25 Aug 2015 Discontinued - Phase-III for Myocardial infarction in Japan (IV)
  • 15 Jan 2008 Efficacy and adverse events data from an independent trial in acute myocardial infarction released by Asubio ,,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top